Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart G Baker

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 31, 2025
Letter to the editor regarding "Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies"Stuart G Baker, Ruth Etzioni
Journal of the National Cancer Institute|May 20, 2016
Evaluating Markers for Guiding TreatmentStuart G Baker, Marco Bonetti
BMJ (Clinical Research Ed.)|May 13, 2006
Common susceptibility genes for cancer: search for the end of the rainbowStuart G Baker, Jaakko Kaprio
Journal of the National Cancer Institute|February 29, 2024
Prediagnostic evaluation of multicancer detection tests: design and analysis considerationsStuart G Baker, Ruth Etzioni
Biomarker Insights|August 22, 2020
Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer ScreeningStuart G Baker, Barnett S Kramer
BMC Medical Research Methodology|November 14, 2002
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?Stuart G Baker, Barnett S Kramer
BMC Medical Research Methodology|June 18, 2003
Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomesStuart G Baker, Barnett S Kramer
Journal of the National Cancer Institute|December 25, 2012
Surrogate endpoint analysis: an exercise in extrapolationStuart G Baker, Barnett S Kramer
Chance (New York, N.Y.)|July 3, 2024
Multiple discoveries in causal inference: LATE for the partyStuart G Baker, Karen S Lindeman
Journal of Medical Screening|April 18, 2008
Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening testsStuart G Baker, Barnett S Kramer
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 31, 2025
Letter to the editor regarding "Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies"Stuart G Baker, Ruth Etzioni
Journal of the National Cancer Institute|May 20, 2016
Evaluating Markers for Guiding TreatmentStuart G Baker, Marco Bonetti
BMJ (Clinical Research Ed.)|May 13, 2006
Common susceptibility genes for cancer: search for the end of the rainbowStuart G Baker, Jaakko Kaprio
Journal of the National Cancer Institute|February 29, 2024
Prediagnostic evaluation of multicancer detection tests: design and analysis considerationsStuart G Baker, Ruth Etzioni
Biomarker Insights|August 22, 2020
Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer ScreeningStuart G Baker, Barnett S Kramer
BMC Medical Research Methodology|November 14, 2002
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?Stuart G Baker, Barnett S Kramer
BMC Medical Research Methodology|June 18, 2003
Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomesStuart G Baker, Barnett S Kramer
Journal of the National Cancer Institute|December 25, 2012
Surrogate endpoint analysis: an exercise in extrapolationStuart G Baker, Barnett S Kramer
Chance (New York, N.Y.)|July 3, 2024
Multiple discoveries in causal inference: LATE for the partyStuart G Baker, Karen S Lindeman
Journal of Medical Screening|April 18, 2008
Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening testsStuart G Baker, Barnett S Kramer
Pageof 12